Search clinical trials for: AZD1446

Total 94 results

AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers (SAD)

Healthy

Sweden
AstraZeneca

Completed

A Bioavailability Study Comparing Modified-release Capsules and Immediate Release Capsules in Fed and Fasting Conditions

Healthy

Sweden
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses

Healthy

Japan
AstraZeneca

Completed

Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.

Adult ADHD

United States
AstraZeneca

Completed

A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers

Healthy

Sweden
AstraZeneca

Completed

4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (ROBIN)

Mild to Moderate Alzheimer's Disease

Czech Republic, Hungary, Slovakia
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics With Single and Multiple Ascending Doses of AZD1446

Healthy

Sweden
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects (PK)

Breast Cancer

United States
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single and Multiple Doses of AZD1446 to Japanese Subject

Healthy

Japan
AstraZeneca

Terminated

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Gastric Cancer | Advanced Solid Malignancies | Solid Tumour | Child-Pugh A to B7 Advanced Hepatocellular Carcinoma | EGFR and/or ROS Mutant NSCLC | Lung Metastasis Carcinoma

Korea, Republic of
AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults

Healthy Volunteer | Coronavirus Disease 2019 (COVID-19)

China
AstraZeneca

Completed

Positron Emission Tomography (PET) Study

Healthy

Sweden
AstraZeneca

Completed

Phase I Double-blind, Placebo-controlled Study of AZD7442

COVID-19

Japan
AstraZeneca

Completed

A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

Healthy

United States
AstraZeneca

Completed

A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes (MAD)

Type 2 Diabetes

United States
AstraZeneca

Terminated

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Lymphoma | Multiple Myeloma | Advanced Solid Tumors | Hematologic Malignancies

United States
AstraZeneca
University of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...

Completed

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Primary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia Myelofibrosis

United States, France
AstraZeneca

Completed

To Evaluate the Bioavailability of a Tablet of AZD1656

Type 1 Diabetes

United States
AstraZeneca

Completed

Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM) (ADME)

Type II Diabetes Mellitus

United States
AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults

Coronavirus Disease 2019 (COVID-19)

China
AstraZeneca

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Spain, Canada, United Kingdom, Italy, Germany, Australia, United States, Taiwan, France, Korea, Republic of, China
AstraZeneca

Terminated

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

Solid Malignancies

United States
AstraZeneca

Completed

To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

Glucose Lowering

United States
AstraZeneca

Completed

A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers

Healthy Volunteers

United States
AstraZeneca

Completed

Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)

Sensitivity in Esophagus

Denmark, Sweden
Queen Mary University of London
AstraZeneca

Active, not recruiting

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce (ADOPTION)

Diabetes Mellitus, Type 2 | End Stage Renal Disease | Type 2 Diabetes | Renal Transplant | Kidney Transplant; Complications

United Kingdom
AstraZeneca

Completed

AZD1386 Japanese Multiple Ascending Dosing Study (JMAD)

Chronic Pain

Japan
AstraZeneca

Completed

Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236

Healthy Volunteer

Japan
AstraZeneca

Withdrawn

Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis (CYBER)

Cystic Fibrosis

Netherlands, Poland, Spain, Canada
St George Street Capital

Completed

AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 (ARCADIA)

Covid19

Czechia, Romania, United Kingdom
AstraZeneca

Completed

A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients (BICO)

Chronic Obstructive Pulmonary Disease

Denmark, Finland, Norway, Netherlands
AstraZeneca

Terminated

Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee (OA19)

Pain

Bulgaria, Poland, Hungary, Finland, Canada, Slovakia, Japan
AstraZeneca

Completed

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients (JMAD)

Type 2 Diabetes

Japan
AstraZeneca

Completed

AZD1419 Ph2a Study (INCONTRO)

Asthma

Denmark, Sweden, Hungary, Poland
AstraZeneca

Completed

Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Japan
AstraZeneca

Completed

Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients (CERA)

Chronic Obstructive Pulmonary Disease

Bulgaria, Germany, Hungary, Finland, Slovakia
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386 (MAD)

Chronic Pain

United Kingdom
AstraZeneca
Parexel

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

Healthy Participants

United States
University of Edinburgh
NHS Lothian

Completed

Imaging FIB ONE in the Human Lung Using Endomicroscopy (FIB ONE)

Fibrosis | Lung Cancer

United Kingdom
AstraZeneca

Completed

AZD9496 First Time in Patients Ascending Dose Study

ER+ HER2- Advanced Breast Cancer

United States, United Kingdom, Korea, Republic of
AstraZeneca

Completed

Formulation and Food Effect Study of AZD1386 in Healthy Volunteers

Pharmacokinetics
AstraZeneca

Terminated

Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain (AVANT)

Pain | Neuropathic Pain

France, United Kingdom, Canada, Denmark
AstraZeneca

Terminated

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Spain, United States, Korea, Republic of, France, Portugal, Australia, Italy
AstraZeneca

Completed

To Evaluate 24-hr Glucose After OD vs BD AZD1656

Type II Diabetes

United States
AstraZeneca

Completed

Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386

Pain

United Kingdom
AstraZeneca

Completed

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

Type II Diabetes

United States
AstraZeneca

Recruiting

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin Lymphoma

Korea, Republic of, United States, Japan, Australia, Taiwan
AstraZeneca
Parexel

Completed

AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19

COVID-19

United Kingdom
AstraZeneca

Completed

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin

Type 2 Diabetes

United States, India

3

Subscribe